A Study of RC48-ADC in Advanced Melanoma Subjects With HER2-positive
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase IIa, single-arm, single-center, open-label clinical trial aims to evaluate
the effectiveness and safety of RC48-ADC in the treatment of HER2-positive advanced melanoma.